Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnosis of Parvovirus B19 in Pregnancy Enhanced

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
The Iam Parvo assay is a rapid quantitative molecular assay that expands DiaSorin's diagnostic portfolio for this potentially life-threatening virus.

Parvovirus B19 (B19V) is a common childhood infection.  It causes particular concern where a pregnant woman has had contact with a B19V infected individual, or where maternal B19V infection is suspected.    During pregnancy, from as early as 6 weeks gestation, B19V can transfer from mother to foetus across the placenta. Such infection may cause hydrops fetalis, miscarriage or poor outcomes (including severe neurological disease) in surviving babies.1

Diagnosis of maternal infection relies on the detection of IgM and IgG antibodies. The presence of IgG antibodies to B19V indicates a previous infection, but it is estimated that approximately 25 to 45% of women of childbearing age do not possess these antibodies and are therefore susceptible to infection.2 

First line serology testing will indicate current active B19V infection.  However, when serological test results are negative but infection is still suspected, clinicians can rapidly confirm diagnosis using the new, highly sensitive, Iam Parvo molecular assay.  This confirmation is particularly important in the 8 - 12 week period after maternal infection, when the sensitivity of IgM antibody detection varies from 63% to 70% and serological testing alone may not give the full picture.4  Rapid diagnosis of infection allows the foetus to be monitored and appropriate care referrals to be made.

“Iam Parvo is a molecular assay that, when used together with serological testing, enhances the clinical management of B19V-complicated pregnancies,” said Paul Eros, Global Vice President Molecular, DiaSorin. “With this molecular assay launch we underpin DiaSorin’s leadership in Parvovirus B19 testing and demonstrate our commitment to providing a complete diagnostic solution for this important infectious disease. Iam Parvo is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison® Iam molecular instrument, a benchtop device which meets the needs of laboratories by providing them with a cost-effective, scaleable, molecular diagnostic solution.” 

Calibrated against the WHO standard for B19V, Iam Parvo provides exceptional time-to-result benefits when compared to PCR, with equivalent specificity.  The Liaison Iam instrument uses DiaSorin’s proprietary Q-LAMP technology.

“People should not confuse DiaSorin Q-LAMP with conventional LAMP technology”, continues Eros, “DiaSorin Q-LAMP assays provide many advantages.  They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction”.    

The Iam Parvo assay is CE-IVD validated for use outside of the USA and Canada only.

For more information about the Iam Parvo assay and the Liaison Iam molecular instrument email info@ie.diasorin.com or visit www.diasorin.com

 1.    Dijkmans A.C. et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr. Opin. Obstet. Gynecol. (2012) 24:95-101. 

2.    Rohrer C., Gartner B., Sauerbrei A. et al. Seroprevalence of Parvovirus B19 in the German population.  Epidemiol. Infect. (2008), 36:1-7

3.    Bredl S., Plentz A., Wenzel J.J. et al. False negative serology in patients with acute Parvovirus B19 infection. J. Clin. Viro. (2011) 51:115-120 

4.    Enders M., Helbig S, Hunjet A. et al. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of gestational Parvovirus B19 infection. J. Virol. Methods (2007) 146:409-413).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!